Genentech--Capacity Planning Custom Case Solution & Analysis

Evidence Brief

Financial Metrics

• Total revenue for the fiscal year 2004 reached 4.6 billion dollars.
• Capital expenditure for the CCP2 facility in Vacaville is approximately 600 million dollars.
• Product sales for Avastin, Herceptin, and Rituxan represent the majority of biologics income.
• The cost to build a new large scale manufacturing site ranges from 600 million to 1 billion dollars.
• Inventory carrying costs for biologics are high due to specialized storage requirements.

Operational Facts

• Manufacturing lead time for a new facility is 3 to 5 years from groundbreaking to FDA approval.
• The South San Francisco facility provides 1000 liter to 12000 liter scale production.
• The Vacaville CCP1 facility contains 12 bioreactors at 12000 liters each.
• The CCP2 expansion adds 8 bioreactors at 25000 liters each, significantly increasing scale.
• Batch success rates and protein yields vary significantly between different antibody products.
• Contract manufacturing agreements with Lonza provide a secondary source but offer less control over timing.

Stakeholder Positions

• Arthur Levinson, Chief Executive Officer: Prioritizes patient access and ensures that no patient goes without medicine.
• David Ebersman, Chief Financial Officer: Focuses on capital efficiency and the risks associated with idle capacity.
• Pat Yang, Head of Manufacturing: Concerned with the technical challenges of scaling up from 12000 to 25000 liter tanks.
• Commercial Teams: Forecast high demand based on new indications for Avastin and Herceptin.

Information Gaps

• The case does not provide the exact probability of success for upcoming clinical trial readouts.
• Specific pricing terms for the Lonza contract expansion are not detailed.
• Competitor manufacturing capacity and their potential to capture market share during a shortage are not fully quantified.

Strategic Analysis

Core Strategic Question

• Genentech must decide how to scale manufacturing capacity to meet volatile demand for life saving oncology drugs.
• The central dilemma is the 5 year lead time for capacity which forces decisions before clinical trial results are known.
• Underestimation leads to product shortages and loss of life; overestimation leads to massive capital waste and idle facility costs.

Structural Analysis

The biologics industry features high barriers to entry due to capital intensity and regulatory complexity. Supplier power is significant for specialized equipment, but the primary constraint is internal capacity. Rivalry is increasing as competitors develop biosimilars and alternative therapies. The Value Chain is anchored by manufacturing excellence; a failure in production breaks the entire commercial strategy. Using a Real Options lens, the investment in CCP3 serves as an insurance policy against the high cost of a stock out.

Strategic Options

Option 1: Aggressive Capacity Expansion (Build CCP3 Now)

• Rationale: Ensures supply for all potential demand scenarios and clinical successes.
• Trade offs: High risk of idle capacity if clinical trials fail or demand slows.
• Requirements: Immediate commitment of 600 million to 800 million dollars in capital.

Option 2: Hybrid Strategy (Yield Optimization and CMO Reliance)

• Rationale: Delay CCP3 by focusing on increasing the grams per liter output of existing tanks and using Lonza for overflow.
• Trade offs: Yield improvements are technically uncertain; CMO capacity may not be available when needed.
• Requirements: Heavy investment in R and D for process engineering and contract negotiations.

Option 3: Phased Modular Construction

• Rationale: Build the shell of CCP3 but only equip the bioreactors as demand crystallizes.
• Trade offs: Higher total cost than building all at once; still requires significant upfront time for the shell.
• Requirements: Flexible engineering design and staged capital approvals.

Preliminary Recommendation

Genentech should pursue Option 1. In the oncology market, the cost of a shortage is not just financial; it is a permanent loss of market leadership and a violation of the patient first mission. The financial downside of idle capacity is preferable to the catastrophic risk of a product outage during a period of rapid growth.

Implementation Roadmap

Critical Path

• Month 1 to 6: Finalize engineering specifications for CCP3 and secure board approval for initial site preparation.
• Month 6 to 18: Complete shell construction and begin procurement of long lead time stainless steel bioreactors.
• Month 12 to 36: Execute tech transfer protocols to ensure 25000 liter tanks match the quality profiles of smaller scale production.
• Month 36 to 48: Conduct FDA validation runs and submit supplemental Biologics License Applications.

Key Constraints

• The availability of specialized process engineers to manage multiple simultaneous expansions (CCP2 and CCP3).
• Regulatory timelines which are outside of company control and require strict adherence to validation protocols.
• The technical risk of protein aggregation or yield loss when moving to the 25000 liter scale.

Risk Adjusted Implementation Strategy

To mitigate the risk of overcapacity, the company will implement a staggered hiring plan for the Vacaville site. Training for new technicians will begin 12 months before the anticipated FDA approval date. If clinical trials for new indications fail, the company will pivot CCP3 to support the pipeline of early stage molecules, effectively using the site as a launch facility to offload pressure from the South San Francisco plant. This flexibility ensures the asset remains utilized even if the primary demand drivers shift.

Executive Review and BLUF

BLUF

Genentech must approve the immediate construction of the CCP3 facility. The 5 year lead time for biologics manufacturing creates an asymmetric risk profile where the cost of a product shortage far outweighs the cost of carrying excess capacity. With revenue growth exceeding 40 percent and multiple late stage clinical trials pending, the current trajectory will exhaust CCP2 capacity shortly after its launch. Building CCP3 is the only path that guarantees patient access and protects market share in the oncology segment. Speed is the primary strategic imperative.

Dangerous Assumption

The analysis assumes that manufacturing yields will remain stable or improve at the 25000 liter scale. If the scale up to larger tanks results in lower protein concentration or higher batch failure rates, the projected capacity will be insufficient even with the addition of CCP3.

Unaddressed Risks

Unconsidered Alternative

The team did not fully explore the acquisition of an existing manufacturing facility from a struggling competitor or a mid sized biotech firm. While integration is difficult, this could potentially shorten the 5 year window to 2 years by bypassing the initial construction phases.

Verdict

APPROVED FOR LEADERSHIP REVIEW